NCT06057038View on ClinicalTrials.gov

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

November 24, 2023

Primary Completion Date

March 26, 2026

Study Completion Date

December 26, 2026

Conditions

Malignant Solid Tumor

Interventions

BIOLOGICAL

GEN1042

Intravenous

DRUG

Pembrolizumab

Intravenous

DRUG

Cisplatin

Intravenous

DRUG

Carboplatin

Intravenous

DRUG

5-Fluorouracil

Intravenous

Trial Locations (3)

Unknown

National Cancer Center East, Kashiwa

National Cancer Center Hospital, Tokyo

Tokyo Medical University Hospital, Tokyo

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

BioNTech SE

INDUSTRY

lead

Genmab

INDUSTRY